Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
June 10, 2019
CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
BERKELEY HEIGHTS, N.J., June 10, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
June 10, 2019
Edap Tms: EDAP Announces Positive Outcome from CPT Panel for HIFU Reimbursement in the U.S.
LYON, France, June 10, 2019 -- EDAP TMS SA (EDAP) (“the Company”), the global leader in therapeutic ultrasound, today announced that the American Medical Association’s ...
June 10, 2019
Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media
Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced ...
June 10, 2019
CohBar poster available on preclinical results showing efficacy of a new family of mitochondria based therapeutics in a type 2 diabetes model as presented at the American Diabetes Association 79th Scientific Sessions
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company focused on developing mitochondria based therapeutics to treat ...
June 10, 2019
electroCore Announces Frank R. Amato to Step Down as Chief Executive Officer
BASKING RIDGE, N.J., June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be ...
June 10, 2019
Isofol Announces Election of Three New Board Members
GOTHENBURG, Sweden, June 10, 2019 /PRNewswire/ -- Isofol Medical AB (publ) (Nasdaq First North Premier: ISOFOL), today announced the election  of three new members to ...
June 6, 2019
Innate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
Marseille, France, June 6, 2019, 7:00 AM CEST -- Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that it has enrolled ...
June 6, 2019
Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion
Boston, MA and Copenhagen, Denmark – June 6, 2019 –Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL, company announcement No. 19/2019) announced today that ...
June 6, 2019
OncoCyte Announces Chief Executive Officer Transition
ALAMEDA, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung ...
June 6, 2019
Athenex Provides an Update on its Chongqing API Plant
BUFFALO, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
June 6, 2019
Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis
BUFFALO, N.Y. and TAIPEI, Taiwan, June 06, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of ...
June 6, 2019
Athenex and PharmaEssentia Announce Positive Early Signals of Clinical Activity of KX2-391 (INN: tirbanibulin) in Patients with Psoriasis
BUFFALO, N.Y. and TAIPEI, Taiwan, June 06, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of ...
June 6, 2019
Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
CRANBURY, N.J., June 6, 2019 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of ...
June 6, 2019
INSIGHT: First Patient Dosed in the 4th arm called “INSIGHT-004”
SYDNEY, Australia, June 06, 2019 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments ...
June 6, 2019
Urovant Sciences to Report Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
IRVINE, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Urovant Sciences (UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it ...
June 6, 2019
Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
HOPKINTON, Mass., June 06, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
June 6, 2019
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat in Heart Failure Patients
PARIS and NEW YORK, June 06, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of ...
June 5, 2019
Reata Announces Presentations at the 56th Congress of the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA)
IRVING, Texas, June 04, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that four abstracts highlighting Reata’s progress in ...
June 5, 2019
Sierra Announces Momelotinib Granted FDA Fast Track Designation
VANCOUVER , June 5, 2019 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on advancing targeted therapeutics for the treatment of ...
June 5, 2019
Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / June 5, 2019 / Oncolytics Biotech® Inc. (ONCY) (ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic ...
Page 4 of 150